✕
Gain Access to exclusive preclinical content.
Complete the form below to gain access to mattis aliquet nunc aliquam tempor. We’ll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文 (Simplified Chinese) | 繁體中文 (Traditional Chinese)
HISTORY
Where we began and why there’s no end in sight.

MediBeacon, in a management buyout in 2012, acquired technology from Mallinckrodt/Covidien. Since then, the company has conducted numerous clinical studies focused on the transdermal detection of proprietary fluorescent agents as a means to measure physiological function.

The company’s intellectual property has expanded substantially and now includes over 35 granted US patents, which cover composition of matter of the company’s pharmaceuticals, as well as algorithms and methods related to the transdermal detection of these patented fluorescent agents.

“Fluorescence techniques could be advantageously applied to humans, and results of human trials are eagerly awaited.”

– American Journal of Physiology: Renal Physiology 2011
INDUSTRY INVESTMENT

In 2015, Pansend Life Sciences of HC2 Holdings, Inc. (NYSE MKT: HCHC) became the largest equity investor in MediBeacon. In 2019, MediBeacon entered into a $30 million investment and exclusive commercialization partnership in Greater China with Huadong Medicine Co., Ltd. Huadong is a leading China-based pharmaceutical company listed on the Shenzhen Stock Exchange.

MediBeacon’s fluorescent agent platform for use in physiological function monitoring has important applications in kidney health, gastrointestinal health, and beyond.
MEDIBEACON TIMELINE
Making technology that is making medical history.*
  • The Transdermal GFR Measurement System (TGFR) is poised to begin its pivotal clinical study in the U.S. and Europe.
  • First-in-human studies are underway to establish the feasibility of fluorescent tracer agent-based systems to quantify the permeability of the gastrointestinal tract in patients with active Crohn’s Disease.
  • The Centers for Medicare & Medicaid Services implement a dedicated ICD-10 code for use with the TGFR (XT25XE5 - Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology, Group 5)
  • MediBeacon enters into a $30 Million investment and exclusive commercialization partnership with Huadong Medicine headquartered in greater China.
  • MediBeacon obtains ISO 13485:2016 Recertification.
  • Introduction of the Transdermal Mini GFR Monitor for preclinical use.
  • FDA grants “Breakthrough Device Status” for MediBeacon’s Transdermal GFR Measurement System.
  • Publication of MediBeacon gut permeability research in Nature Publication – Scientific Reports.
  • Clinical studies demonstrating TGFR use completed on patients with impaired kidney function.
  • MediBeacon presents gastrointestinal permeability research at Digestive Disease Week in Chicago.
  • MediBeacon acquires Mannheim Pharma & Diagnostics (Preclinical business).
  • NIH awards grant to study fluorescent technology for use in ocular angiography.
  • A follow-on grant from the Bill & Melinda Gates Foundation funds MediBeacon continued gastroenterology collaboration with Washington University School of Medicine.
  • Investment in patented fluorescent tracer agents for use in numerous potential medical applications outside of nephrology increases.
  • MediBeacon closes on a $22.4 million staged financing with Pansend Life Sciences, LLC.
  • Results of initial TGFR clinical studies presented at American Society of Nephrology (ASN) Kidney Week.
  • Initial TGFR clinical studies are completed at the University of Maryland.
  • MediBeacon in collaboration with Washington University begins pursuing the use of fluorophore technology in gastroenterology. The work is funded by an initial grant from the Bill & Melinda Gates Foundation.
  • MediBeacon begins human clinical studies at the University of Maryland.
  • MediBeacon acquires outright all technology, market research, patent estate and other related assets from Mallinckrodt.
  • First quarter 2012, U.S. patent issued to MediBeacon for Lumitrace™ (relmapriazin).

At MediBeacon, we measure our success in our ability to create measurable differences that impact global health. Evidence of our advances can be found in the numerous issued global patents.

United States
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 735-0968

Germany
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery Investors Why It's Important Company Overview By the Numbers
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People Quality Commitment News/Media Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of clinical development and are not yet approved for human use.

**The Transdermal GFR Measurement System (TGFR) is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. References on this website to measured kidney function and measured renal function refer to the measured GFR.

Terms and Conditions | Privacy Policy | © 2021 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.